SCHEMBL4680310

SCHEMBL4680310

O=C(OCc1c(F)cc(OCc2ccsc2)cc1F)N1CCNCC1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
ENPP2 Q13822 1/20 0.42
ATXN2 Q99700 1/20 0.42
HTR2C P28335 1/20 0.39
PARP15 Q460N3 1/20 0.39
PARP10 Q53GL7 1/20 0.39
PARP3 Q9Y6F1 1/20 0.39
PARP1 P09874 5/20 0.38
HPGD P15428 1/20 0.36
HRH2 P25021 1/20 0.35
HRH1 P35367 1/20 0.35
SCN7A Q01118 1/20 0.34
KCNH2 Q12809 1/20 0.34
TPSAB1 Q15661 1/20 0.34
TPSD1 Q9BZJ3 1/20 0.34
TPSG1 Q9NRR2 1/20 0.34
DPP4 P27487 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Fumaric Acid SCHEMBL4679362 0.94 CYP1A2 (0.41) CYP1A2CYP2C9CYP2C19ENPP2ATXN2
Fumaric Acid SCHEMBL4679366 0.94 CYP1A2 (0.41) CYP1A2CYP2C9CYP2C19ENPP2ATXN2
SCHEMBL4682708 0.85 HTR2C (0.47) CYP1A2CYP2C9CYP2C19ENPP2ATXN2
SCHEMBL4682705 0.85 HTR2C (0.47) CYP1A2CYP2C9CYP2C19ENPP2ATXN2
SCHEMBL4681034 0.82 HTR2C (0.61) CYP1A2CYP2C9CYP2C19ENPP2ATXN2
SCHEMBL4681036 0.82 HTR2C (0.61) CYP1A2CYP2C9CYP2C19ENPP2ATXN2
SCHEMBL4684566 0.81 SMN1; SMN2 (0.43) CYP1A2CYP2C9CYP2C19HTR2CPARP1
Fumaric Acid SCHEMBL4677772 0.80 HTR2C (0.43) CYP1A2CYP2C9CYP2C19ENPP2ATXN2
Fumaric Acid SCHEMBL4677768 0.80 HTR2C (0.43) CYP1A2CYP2C9CYP2C19ENPP2ATXN2
Fumaric Acid SCHEMBL4677775 0.80 HTR2C (0.43) CYP1A2CYP2C9CYP2C19ENPP2ATXN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1343775-B1 PIPERAZINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2008-06-04 EP disclosed
US-7022707-B2 Piperazine derivatives HOFFMAN-LA ROCHE INC. (US) 2006-04-04 US disclosed
US-20040235859-A1 Novel piperazine derivatives ADAMS DAVID REGINALD (GB) 2004-11-25 US disclosed
EP-1343775-A2 PIPERAZINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2003-09-17 EP disclosed
US-20020143020-A1 Novel piperazine derivatives VERNALIS RESEARCH LIMITED (GB) 2002-10-03 US disclosed
WO-2002048124-A2 PIPERAZINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2002-06-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020143020-A1 Novel piperazine derivatives CYP4B1, UGT1A1, CYP1B1 CYP1A2 14/4885CYP2C9 239/4885CYP2C19 222/4885
US-20040235859-A1 Novel piperazine derivatives CYP4B1, UGT1A1, CYP1B1 CYP1A2 14/4885CYP2C9 239/4885CYP2C19 222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.